Merck & Co., Inc. - Jun 2, 2021 Form 4 Insider Report for Organon & Co. (OGN)

Role
10%+ Owner
Signature
Merck & Co., Inc. /s/ Kelly E.W. Grez, Deputy Corporate Secretary
Stock symbol
OGN
Transactions as of
Jun 2, 2021
Transactions value $
$0
Form type
4
Date filed
6/4/2021, 04:46 PM
Previous filing
May 7, 2021
Next filing
Jan 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGN Common Stock Other -254M -100% 0 Jun 2, 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Merck & Co., Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Separation and Distribution Agreement, dated as of June 2, 2021, Merck & Co., Inc. ("Merck") distributed to the holders of its common stock by means of a pro-rata distribution without consideration an aggregate of 253,516,000 shares of common stock of Organon & Co. (the "Separation").
F2 In connection with the Separation, the 100 shares of common stock of Organon & Co. held by Merck were reclassified into 253,516,000 shares of common stock of Organon & Co.